Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA-sequencing in drug-resistant acute myeloid leukemia

ABSTRACT: mRNA-sequencing in drug-resistant acute myeloid leukemia

PROVIDER: PRJNA828413 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18829169_1.fastq.gz	Fastqsanger.gz
	SRR18829169_2.fastq.gz	Fastqsanger.gz
	SRR18829170_1.fastq.gz	Fastqsanger.gz
	SRR18829170_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Drug-resistant acute myeloid leukemia

Project description:Drug-resistant acute myeloid leukemia

| PRJNA828404 | ENA

m7G-MeRIP-sequencing of mRNA in drug-resistant acute myeloid leukemia

Project description:m7G-MeRIP-sequencing of mRNA in drug-resistant acute myeloid leukemia

| PRJNA828412 | ENA

Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia

Project description:Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia

| PRJNA914332 | ENA

Loss of DKM6A confers drug resistance in acute myeloid leukemia

Project description:Loss of DKM6A confers drug resistance in acute myeloid leukemia

| PRJNA526898 | ENA

Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia

Project description:Label-free quantitation dataset from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.

2022-03-09 | MSV000089029 | MassIVE

mRNA-sequencing in drug-resistant acute myeloid leukemia

Project description:mRNA sequencing for AML cells(HL-60) and drug-resistant AML Cells(HL60/MX2).

2022-04-23 | GSE201095 | GEO

Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia

Project description:A deep-scale proteome and phosphoproteome database from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.

2022-03-07 | MSV000089012 | MassIVE

Stabilizing the Proteomes of Acute Myeloid Leukemia Cells: Implications for Cancer Proteomics

Project description:Data dependent analysis of acute myeloid leukemia samples in the presence and absence of the serine protease inhibitor DFP

2023-07-26 | MSV000092526 | MassIVE

caArray_golub-00392: Gefitinib (Iressa) induces myeloid differentiation of acute myeloid leukemia

Project description:Cure rates for patients with acute myeloid leukemia (AML) remain low despite ever-increasing dose intensity of cytotoxic therapy. In an effort to identify novel approaches to AML therapy, we recently reported a new method of chemical screening based on the modulation of a gene expression signature of interest. We applied this approach to the discovery of AML-differentiation-promoting compounds. Among the compounds inducing neutrophilic differentiation was DAPH1 (4,5-dianilinophthalimide), previously reported to inhibit epidermal growth factor receptor (EGFR) kinase activity. Here we report that the Food and Drug Administration (FDA)-approved EGFR inhibitor gefitinib similarly promotes the differentiation of AML cell lines and primary patient-derived AML blasts in vitro. Gefitinib induced differentiation based on morphologic assessment, nitro-blue tetrazolium reduction, cell-surface markers, genome-wide patterns of gene expression, and inhibition of proliferation at clinically achievable doses. Importantly, EGFR expression was not detected in AML cells, indicating that gefitinib functions through a previously unrecognized EGFR-independent mechanism. These studies indicate that clinical trials testing the efficacy of gefitinib in patients with AML are warranted. golub-00392 Assay Type: Gene Expression Provider: Affymetrix Array Designs: HG-U133A, HG-U133A_2 Organism: Homo sapiens (ncbitax) Material Types: cell, total_RNA, synthetic_RNA, organism_part, whole_organism*Cell Types: Disease States: Acute Myeloid Leukemia, Normal, Acute Myeloid Leukemia

2015-05-16 | E-GEOD-68954 | biostudies-arrayexpress

AML_profiling - Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome and tyrosine-phosphatome in acute myeloid leukemia

Project description:LC-MS/MS was used to profile total phosphotyrosine phosphatase in acute myeloid leukemia (AML) in order to find potential biomarkers, drug targets, signatures for AML classification, and its relationship with total phosphotyrosine amount in the samples.

2017-02-16 | PXD001170 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data